A class of cholesterol-lowering drugs first approved decades ago, and now sold in generic form for pennies a pill, remains one of the most effective tools modern medicine has for preventing heart attacks. Statins work by interrupting a specific step in the liver’s process for making cholesterol, and the resulting drop in low-density lipoprotein, the form of cholesterol most closely tied to clogged arteries, has been shown across dozens of large clinical trials to meaningfully reduce the risk of heart attack, stroke and cardiovascular death. Despite newer and far more expensive cholesterol drugs entering the market in recent years, statins remain the foundation of cardiovascular prevention for millions of patients worldwide.
How Statins Interrupt Cholesterol Production in the Liver
Statins work by blocking an enzyme called HMG-CoA reductase, which the liver relies on to manufacture cholesterol. With that step interrupted, the liver produces less cholesterol on its own and compensates by pulling more low-density lipoprotein, often called LDL or “bad” cholesterol, out of the bloodstream, which lowers overall LDL levels in the blood. Because elevated LDL is one of the primary drivers of atherosclerosis, the gradual buildup of fatty plaque inside artery walls, reducing it directly addresses one of the root mechanical causes of heart attacks and strokes rather than simply treating symptoms after the fact. Statins also appear to have effects beyond cholesterol reduction alone, including modest anti-inflammatory properties and a tendency to stabilize existing arterial plaque, making it less likely to rupture and trigger a clot.
The Evidence Behind Their Reputation as a Heart Attack Preventer
The case for statins rests on an unusually large body of clinical trial evidence, accumulated over more than three decades and involving hundreds of thousands of patients across dozens of randomized trials. Those trials have consistently found that lowering LDL cholesterol with statins reduces the relative risk of heart attack, stroke and cardiovascular death, both in people who have already had a cardiovascular event and in people who have not but carry elevated risk factors such as high cholesterol, diabetes or a family history of heart disease. The magnitude of benefit scales with how much LDL cholesterol drops and how long a person stays on the medication, which is why cardiologists generally treat statins as a long-term, ongoing therapy rather than a short-term fix.
Why the Drug Class Became So Inexpensive
Part of what makes statins remarkable from a public health standpoint is cost. The most widely prescribed statins, including atorvastatin and simvastatin, lost patent protection years ago and are now manufactured as generics, often available for just a few dollars a month even without insurance. That combination of strong clinical evidence and extremely low cost is unusual in modern pharmaceuticals, where new drugs with far more modest benefits frequently carry price tags hundreds of times higher. Health economists studying cardiovascular prevention have repeatedly identified statins as one of the most cost-effective interventions in all of medicine, since the price of preventing a single heart attack or stroke through years of statin therapy is a fraction of the cost of treating one after it occurs.
Side Effects and the Ongoing Debate Over Who Should Take Them
Statins are not free of downsides, and the discussion around them has become one of the more debated topics in preventive cardiology. The most commonly reported side effect is muscle aches, which affect a meaningful minority of patients, though large trials have found that the true rate directly caused by the drug is lower than the rate reported in everyday clinical practice, since muscle pain is common in the general population regardless of medication. Statins have also been associated with a modestly increased risk of developing type 2 diabetes in some patients, a tradeoff that guidelines generally judge to be outweighed by the cardiovascular benefit for people at meaningful risk. Because LDL cholesterol levels alone do not capture a person’s full cardiovascular risk, current prescribing guidelines increasingly weigh statins against a broader risk calculation that includes age, blood pressure, smoking status and family history.
Why Statins Remain the Default Choice Despite Newer Alternatives
In recent years, newer cholesterol-lowering drugs, including a class of injectable medications known as PCSK9 inhibitors, have reached the market with the ability to lower LDL cholesterol even further than statins alone. Those newer drugs remain far more expensive and are generally reserved for patients who cannot tolerate statins or whose cholesterol remains dangerously high despite statin therapy, rather than replacing statins as a starting point. According to MedlinePlus, statins are typically the first medication doctors consider for lowering cholesterol precisely because of that combination of proven benefit, manageable side effects and low cost. For the vast majority of patients at elevated cardiovascular risk, that durability, more than four decades after the first statin reached the market, is part of why the drug class is still described as one of the most successful interventions in the history of preventive medicine.
This article was produced with the assistance of AI and reviewed by Morning Overview editors.
More from Morning Overview
- Card skimmers hidden on gas pumps and ATMs are draining accounts, and here’s the tell
- The FBI says hackers are hijacking outdated home routers, and it named the models to check
- Older Teslas are wearing out in ways early owners never saw coming
- A common childhood virus is now tied to multiple sclerosis years later
